Editas Medicine (EDIT) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$25.1 million.
- Editas Medicine's Profit After Tax rose 5958.06% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.8 million, marking a year-over-year increase of 509.9%. This contributed to the annual value of -$237.1 million for FY2024, which is 5474.13% down from last year.
- Per Editas Medicine's latest filing, its Profit After Tax stood at -$25.1 million for Q3 2025, which was up 5958.06% from -$53.2 million recorded in Q2 2025.
- Over the past 5 years, Editas Medicine's Profit After Tax peaked at -$18.9 million during Q4 2023, and registered a low of -$76.1 million during Q1 2025.
- Over the past 5 years, Editas Medicine's median Profit After Tax value was -$53.2 million (recorded in 2025), while the average stood at -$50.4 million.
- As far as peak fluctuations go, Editas Medicine's Profit After Tax tumbled by 59983.37% in 2021, and later surged by 6892.55% in 2023.
- Quarter analysis of 5 years shows Editas Medicine's Profit After Tax stood at -$41.4 million in 2021, then plummeted by 46.58% to -$60.7 million in 2022, then skyrocketed by 68.93% to -$18.9 million in 2023, then tumbled by 140.52% to -$45.4 million in 2024, then soared by 44.67% to -$25.1 million in 2025.
- Its Profit After Tax was -$25.1 million in Q3 2025, compared to -$53.2 million in Q2 2025 and -$76.1 million in Q1 2025.